Neomend's vascular closure study gains FDA nod:
This article was originally published in Clinica
Executive Summary
Neomend is to begin a US trial to evaluate its arterial closure device in treating patients who have received punctures to the femoral artery in the leg. The device is intended to achieve haemostasis of arterial punctures in patients who have undergone diagnostic or interventional procedures. It can be used safely in a variety of patients, including those requiring immediate or chronic repunctures, closure of either antegrade or retrograde punctures and those taking GP IIb/IIIa inhibitors, said the Sunnyvale, California firm.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.